← Back to Clinical Trials
Recruiting NCT06861673

COCONUT Study Concomitant PVI and LAAC

Trial Parameters

Condition Atrial Fibrillation (AF)
Sponsor Asklepios proresearch
Study Type OBSERVATIONAL
Phase N/A
Enrollment 60
Sex ALL
Min Age N/A
Max Age N/A
Start Date 2025-03-01
Completion 2026-04-01
Interventions
Pulmonary vein isolation

Brief Summary

In patients with non-valvular AF, at high stroke risk, and who are ineligible for long-term oral anticoagulation LAAC could be an alternative to anticoagulation and safety and efficacy has been shown in several studies and registries.8 While PVI and LAAC are both conducted in the left atrium and share the same access route, a combined concomitant approach might be beneficial for patients but is not conventionally practiced. Due to significantly shorter procedures times and high safety profile PFA based catheter ablation may be advantageous for the combined approach of PVI and LAAC. We are performing a word-wide, retrospective, multicenter registry study focusing on patients with concomitant Farapulse PFA based PVI and LAAC (WATCHMAN Flx, Boston Scientific). To evaluate safety, efficacy and efficiency in a multicenter study the COCONUT study was conducted.

Eligibility Criteria

Inclusion Criteria: Indicatio for PVI and LAAC Exclusion Criteria: Not eligible for any of the procedures PVI and LAAC

Related Trials